Literature DB >> 12524653

Positron emission tomography imaging in nonmalignant thoracic disorders.

Abass Alavi1, Naresh Gupta, Jean-Louis Alberini, Marc Hickeson, Lars-Eric Adam, Peeyush Bhargava, Hongming Zhuang.   

Abstract

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12524653     DOI: 10.1053/snuc.2002.127291

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  45 in total

1.  Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease.

Authors:  Mike Sathekge; Alex Maes; Yves D'Asseler; Mariza Vorster; Harlem Gongxeka; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-18       Impact factor: 9.236

Review 2.  Biomechanics of the cardiovascular system: the aorta as an illustratory example.

Authors:  Ghassan S Kassab
Journal:  J R Soc Interface       Date:  2006-12-22       Impact factor: 4.118

Review 3.  The pulmonary nodule: clinical and radiological characteristics affecting a diagnosis of malignancy.

Authors:  L Cardinale; F Ardissone; S Novello; M Busso; F Solitro; M Longo; D Sardo; M Giors; C Fava
Journal:  Radiol Med       Date:  2009-05-29       Impact factor: 3.469

4.  Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.

Authors:  Stephanie L Davis; Eric L Nuermberger; Peter K Um; Camille Vidal; Bruno Jedynak; Martin G Pomper; William R Bishai; Sanjay K Jain
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  The clinical value of F-18 FDG PET/CT in differentiating malignant from benign lesions in pneumoconiosis patients.

Authors:  Eun Kyoung Choi; Hye Lim Park; Ie Ryung Yoo; Seung Joon Kim; Young Kyoon Kim
Journal:  Eur Radiol       Date:  2019-07-23       Impact factor: 5.315

6.  Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.

Authors:  Anne Roivainen; Sannamari Hautaniemi; Timo Möttönen; Pirjo Nuutila; Vesa Oikonen; Riitta Parkkola; Luminita Pricop; Rudyard Ress; Nicholas Seneca; Marko Seppänen; Timo Yli-Kerttula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

7.  Feasibility of assessing [(18)F]FDG lung metabolism with late dynamic PET imaging.

Authors:  Eric Laffon; Henri de Clermont; Jean-Marc Vernejoux; Jacques Jougon; Roger Marthan
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

8.  Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Authors:  Jinbo Yue; Qiuling Shi; Ting Xu; Melenda Jeter; Ting-Yu Chen; Ritsuko Komaki; Daniel R Gomez; Tinsu Pan; Charles S Cleeland; Zhongxing Liao; Xin Shelley Wang
Journal:  Qual Life Res       Date:  2018-03-16       Impact factor: 4.147

9.  Current clinical use of 18FDG-PET/CT in patients with thoracic and systemic sarcoidosis.

Authors:  Giuseppe Rubini; Salvatore Cappabianca; Corinna Altini; Antonio Notaristefano; Margherita Fanelli; Amato Antonio Stabile Ianora; Artor Niccoli Asabella; Antonio Rotondo
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

10.  Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.

Authors:  Samuel A Jacobs
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.